Formosa Laboratories, Inc. 4746

TWSE · Taiwan · Health Technology

TWD 48.10-0.90 (-1.84%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Formosa Laboratories, Inc. 4746

TWSE · Taiwan · Health Technology

TWD 48.10-0.90 (-1.84%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-13.49% · 6MFull-screen chart

Open TWD 48.95High TWD 48.95Low TWD 47.80Close TWD 48.10Volume 673.55K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: TWD 49.00
Day range: TWD 47.80 – TWD 48.95
52-week range: TWD 45.00 – TWD 68.60
Volume: 673.55K
Market cap: TWD 5.89B
P/E (TTM): 12.2
Dividend yield (annualized): 6.13%
Next earnings date: 2026-11-12
Avg. volume (1Y): 731.80K

Performance

1 week

+0.84%

1 month

+0.84%

3 months

-7.56%

6 months

-6.37%

Year to date

-14.40%

1 year

-25.53%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Taiwan
Exchange: TWSE
Shares outstanding: 120.26M
Employees: 987
ISIN: TW0004746003
Beta: 0.28

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJun 11, 2026

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in Vietnam. Samil, established in 1947, is one of the most prominent Korean manufacturers

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.